Xiaomai Zhou, Ph.D. in Molecular and Cellular Physiology from Tufts University, USA, and a Research Fellow at Harvard Medical School. Dr. Zhou is responsible for molecular and cell biology, antibody generation and engineering, and in vitro functional evaluation of antibody/ADC drugs at DAC Biotechnology. At ImmunoGen, Inc. and Boehringer Ingelheim in the US, he has been responsible for the establishment of  three major technology platforms (phage display, B-cell hybridoma, and the cutting-edge single B cell) for the development of therapeutic antibodies,.  and successfully obtained specific monoclonal antibodies with high affinity to target antigens from single B cells. Dr. Zhou led and participated in multiple antibody and ADC anti-cancer drug projects. He presided over the establishment of dozens of quantitative analysis methods for the evaluation of the functions of therapeutic antibodies at the molecular and cellular levels, and advanced the projects into experimental animal or clinical stages. In his oncology research, Dr. Zhou discovered for the first time in the world a new phosphorylation site on a signal transduction molecule which plays an important role in the anti-apoptosis process of cancer cells, and uncovered its regulatory mechanism, Dr. Zhou is the sole inventor for a influential patent in the field that is related to his discovery. A special antibody based on this new discovery has been successfully industrialized.